BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 10188057)

  • 1. NY-ESO-1 may be a potential target for lung cancer immunotherapy.
    Lee L; Wang RF; Wang X; Mixon A; Johnson BE; Rosenberg SA; Schrump DS
    Cancer J Sci Am; 1999; 5(1):20-5. PubMed ID: 10188057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
    Yoshida N; Abe H; Ohkuri T; Wakita D; Sato M; Noguchi D; Miyamoto M; Morikawa T; Kondo S; Ikeda H; Nishimura T
    Int J Oncol; 2006 May; 28(5):1089-98. PubMed ID: 16596224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
    Sugita M; Geraci M; Gao B; Powell RL; Hirsch FR; Johnson G; Lapadat R; Gabrielson E; Bremnes R; Bunn PA; Franklin WA
    Cancer Res; 2002 Jul; 62(14):3971-9. PubMed ID: 12124329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
    Grah J; Samija M; Juretić A; Sarcević B; Sobat H
    Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
    Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NY-ESO-1 expression and immunogenicity in esophageal cancer.
    Fujita S; Wada H; Jungbluth AA; Sato S; Nakata T; Noguchi Y; Doki Y; Yasui M; Sugita Y; Yasuda T; Yano M; Ono T; Chen YT; Higashiyama M; Gnjatic S; Old LJ; Nakayama E; Monden M
    Clin Cancer Res; 2004 Oct; 10(19):6551-8. PubMed ID: 15475443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of NY-ESO-1 gene in human esophageal carcinoma and its cloning].
    Peng LP; Liu HY; Ran YL; Sun LX; Yu L; Yang ZH
    Ai Zheng; 2002 May; 21(5):469-72. PubMed ID: 12452034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
    Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.
    Wang RF; Johnston SL; Zeng G; Topalian SL; Schwartzentruber DJ; Rosenberg SA
    J Immunol; 1998 Oct; 161(7):3598-606. PubMed ID: 9759882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomic analysis of human sarcoma.
    Lee SY; Obata Y; Yoshida M; Stockert E; Williamson B; Jungbluth AA; Chen YT; Old LJ; Scanlan MJ
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2651-6. PubMed ID: 12601173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas.
    Mashino K; Sadanaga N; Tanaka F; Yamaguchi H; Nagashima H; Inoue H; Sugimachi K; Mori M
    Br J Cancer; 2001 Sep; 85(5):713-20. PubMed ID: 11531257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
    Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
    Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
    Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.
    Kang Y; Hong JA; Chen GA; Nguyen DM; Schrump DS
    Oncogene; 2007 Jun; 26(30):4394-403. PubMed ID: 17260018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.